Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23354173 | 0.98 | CYP2D6 (0.41) | CYP2D6EPHX1CES2CES1HDAC8 | |
| SCHEMBL20491548 | 0.89 | KMT2A (0.35) | CYP2D6EPHX1PRMT3HTT | |
| SCHEMBL21232394 | 0.81 | EPHX1 (0.42) | EPHX1CES2CES1HDAC8HDAC6 | |
| SCHEMBL19540775 | 0.79 | CES2 (0.48) | EPHX1CES2CES1HDAC8HDAC6 | |
| SCHEMBL30231116 | 0.79 | POLB (0.34) | CYP2D6EPHX1RAB9AHTTNPC1 | |
| SCHEMBL23354550 | 0.79 | HDAC3 (0.31) | CYP2D6TSHR | |
| SCHEMBL7368715 | 0.79 | CYP2D6 (0.42) | CYP2D6EPHX1CES2CES1HDAC8 | |
| SCHEMBL9074999 | 0.78 | NOS2 (0.41) | CYP2D6EPHX1CES2CES1HDAC8 | |
| SCHEMBL3091689 | 0.78 | EPHX2 (0.42) | EPHX1CES2CES1HDAC8HDAC6 | |
| SCHEMBL23354852 | 0.77 | HTR1A (0.35) | CYP2D6EPHX1SMN1; SMN2HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010117939-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
| US-9198907-B2 | Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent | PTC THERAPEUTICS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-8841302-B2 | HCV inhibitor and therapeutic agent combinations | PTC THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120087893-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | PTC THERAPEUTICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7875647-B2 | and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders | GREEN CROSS CORPORATION (KR) | 2011-01-25 | — | — | US | disclosed |
| EP-2097410-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Green Cross Corporation (KR) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008105607-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207704-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | THE GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| WO-2008039023-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207704-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR2, CNR1, GPR119 | CYP2D6 1173/4885EPHX1 1882/4885CES2 1071/4885 |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | CYP2D6 4161/4885EPHX1 2107/4885CES2 290/4885 |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | CYP2D6 1333/4885EPHX1 1493/4885CES2 862/4885 |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | CYP2D6 2814/4885EPHX1 1755/4885CES2 769/4885 |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | CYP2D6 773/4885EPHX1 1300/4885CES2 951/4885 |
| US-20120087893-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | PREP, ENPEP, DNPEP | CYP2D6 2922/4885EPHX1 2634/4885CES2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.